Higher local Ebola incidence causes lower child vaccination rates

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic

The CRL is a complete turnaround from the positive recommendation Onpattro received in September from an FDA Advisory Committee (AdCom) panel regarding the label expansion.